Brainstorm Cell Therapeutics INC

Brainstorm Cell Therapeutics announces leadership transitions, appointing Peter Pitts as Executive Chairman and Jacob Frenkel as Senior Advisor.

BrainStorm Cell Therapeutics has appointed former FDA Associate Commissioner Peter J. Pitts to its Board of Directors as it prepares for a Phase 3b ALS trial.

BrainStorm Cell Therapeutics reports Q1 2026 financial results while advancing preparations for its Phase 3b ENDURANCE ALS trial.

BrainStorm Cell Therapeutics announced its full year 2025 financial results, reporting a reduced net loss and highlighting progress on its NurOwn Phase 3b study for ALS, supported by a recent $2 million financing.

Brainstorm Cell Therapeutics Inc. announced a $1 million private placement and an increase in its stock incentive plan pool.

Brainstorm Cell Therapeutics Inc. has entered into a $1 million private placement agreement to sell common stock and warrants for working capital.

Brainstorm Cell Therapeutics faces Nasdaq delisting, ongoing legal challenges, and significant capital needs despite progress in NurOwn's Phase 3b trial design for ALS.

Brainstorm Cell Therapeutics reported Q2 2025 financial results, detailing its Nasdaq delisting, ongoing clinical progress for NurOwn in ALS, and significant capital raising activities amidst continued operating losses.

Brainstorm Cell Therapeutics announces its Q1 2025 financial results, highlighting ongoing efforts to regain Nasdaq compliance and advance its NurOwn program.

Brainstorm Cell Therapeutics reported its third quarter 2024 results, highlighting a decrease in operating expenses and progress in its NurOwn clinical program, while also addressing ongoing financial and legal challenges.

Brainstorm Cell Therapeutics reported its financial results for the second quarter of 2024, highlighting a decrease in operating expenses and progress in its NurOwn clinical program, including a Special Protocol Assessment (SPA) agreement with the FDA.

Brainstorm Cell Therapeutics announced its first quarter 2024 financial results and highlighted a Special Protocol Assessment (SPA) agreement with the FDA for its NurOwn Phase 3b trial in ALS.

Brainstorm Cell Therapeutics Inc. reports a net loss of $10.3 million for 2025, delisting from Nasdaq, and continues development of NurOwn for ALS despite past FDA setbacks.

Brainstorm Cell Therapeutics' 10-K filing reveals ongoing financial challenges and a strategic focus on advancing NurOwn for ALS through a planned Phase 3b trial, despite past regulatory setbacks.

Brainstorm Cell Therapeutics withdrew its Biologics License Application (BLA) for NurOwn to treat ALS after an unfavorable advisory committee vote, but is moving forward with plans for a new Phase 3b trial.

Jacob A Frenkel, a Director of Brainstorm Cell Therapeutics Inc., received 100,000 shares of common stock on July 24, 2026.

Peter Joe Pitts, Executive Chairman and a Director of Brainstorm Cell Therapeutics Inc., received 900,000 shares of common stock on July 24, 2026.

BrainStorm Cell Therapeutics CEO Chaim Lebovits was granted 1.8 million restricted stock units, with half vesting immediately.

EVP & Chief Business Officer Uri Yablonka received an award of 150,000 restricted stock units from BrainStorm Cell Therapeutics.

Interim CFO Alla Patlis received an award of 100,000 restricted stock units from BrainStorm Cell Therapeutics.

BrainStorm Cell Therapeutics director Jacob A. Frenkel was granted 200,000 restricted stock units as part of the company's 2014 Global Share Option Plan.

Brainstorm Cell Therapeutics Inc. is set to hold its annual meeting on June 25, 2025, seeking stockholder votes on director elections, auditor ratification, warrant share issuance approval, and amendments to stock incentive plans.

Brainstorm Cell Therapeutics is holding its annual stockholder meeting on June 25, 2025, to vote on director elections, auditor ratification, a common stock issuance proposal, and amendments to its equity incentive plans.

Brainstorm Cell Therapeutics is holding its 2024 Annual Meeting of Stockholders on September 16, 2024, to vote on several proposals, including the election of directors, ratification of the accounting firm, and amendments to the Certificate of Incorporation and stock incentive plans.

Investment firm Armistice Capital, LLC and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Brainstorm Cell Therapeutics Inc., held for investment purposes.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.99% in Brainstorm Cell Therapeutics Inc. as of December 31, 2024.